#prac — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #prac, aggregated by home.social.
-
https://www.europesays.com/pl/345273/ Spór o remont Mostów Osobowickich. Rura ciepłownicza blokuje rozpoczęcie prac #blokuje #ciepłownicza #Mostów #o #Osobowickich #PL #Poland #Polish #Polska #Polski #prac #remont #rozpoczęcie #rura #spór #wroclaw
-
https://www.europesays.com/pl/344981/ Spór o remont Mostów Osobowickich. Rura ciepłownicza blokuje rozpoczęcie prac #blokuje #ciepłownicza #Mostów #o #Osobowickich #PL #Poland #Polish #Polska #Polski #prac #remont #rozpoczęcie #rura #spór #wroclaw
-
https://www.europesays.com/sk/12230/ Mestské lesy Košice informujú verejnosť o plánovaných ťažbových zásahoch: Výrub stromov v bezprostrednej blízkosti cesty | LesMedium.sk #2026 #bude #budú #ceste #Košice #lesnej #mestské #prác #SK #Slovak #Slovakia #Slovenčina #Slovensko #sokol
-
https://www.europesays.com/it/355715/ Ema, raccomandato il ritiro dal mercato Ue di tutti i medicinali a base di levamisolo #antielminitico #conferma #ema #Health #IT #Italia #Italy #leucoencefalopatia #levamisolo #MercatoUe #prac #rischio #ritiro #Salute
-
Praha - Česká státní správa může během příštích pěti let ztratit až 30.000 kvalifikovaných zaměstnanců, tedy asi 40 procent své současné pracovní síly. Zaměstnanci mladší 30 let nyní tvoří pouze sedm procent úředníků, tedy zhruba polovinu jejich podílu v soukromém sektoru. Vyplývá to ze studie poradenské společnosti Kearney.
-
Praha - Česká státní správa může během příštích pěti let ztratit až 30.000 kvalifikovaných zaměstnanců, tedy asi 40 procent své současné pracovní síly. Zaměstnanci mladší 30 let nyní tvoří pouze sedm procent úředníků, tedy zhruba polovinu jejich podílu v soukromém sektoru. Vyplývá to ze studie poradenské společnosti Kearney.
-
Gierskopp – Kinderschützenfest 1964
https://privatarchiv.rzgierskopp.de/1964/06/kinderschuetzenfest-auf-der-gierskopp-1964/
---
#AlbaumFranz #Antfeld #BeckEdmund #BofingerHermann #CordesKarl #DeutschesKaiserreich #Dokumente #Fest #GastronomieAufDerGierskopp #GaststtteHckelheim #GebudeAufDerGierskopp #Gierskopp #GieseErich #Grndung #HillebrandRobert #HhleWerner #HckelheimFranz #HckelheimFrieda #Kienegge #KriegUndNachkriegszeit #Kultur #Lingelscheid #MuchaGerd #NiggemannRichard #Olsberg #Prac -
The inital DDR5 spec started at DDR5-3200, with a peak bandwidth around 25GiB/s, going up to DDR5-6400 which doubles that to ~50GiB/s.
Now DDR5-8800 has been specced out, at around 70GiB/s.
I see two 'islands' coming; 3x and 4x the original 3200MT, which would be DDR5-9600 and DDR5-12800, the latter hitting a bandwidth of ~100GiB/s.
With latencies not improving, large CPU caches will remain a necessity at the high-end.
-
RT EU Medicines Agency
EMA’s #safety committee, the #PRAC, is reviewing data on the risk of suicidal thoughts and thoughts of self-harm with GLP-1 receptor agonists used for weight loss and for treating type 2 #diabetes.
Read more in the news announcement: https://www.ema.europa.eu/en/news/ema-statement-ongoing-review-glp-1-receptor-agonists https://t.co/Rf3Ly9FGbM🐦🔗: https://n.respublicae.eu/EMA_News/status/1678794781256761346
-
RT EU Medicines Agency
EMA’s #safety committee, the #PRAC, is reviewing data on the risk of suicidal thoughts and thoughts of self-harm with GLP-1 receptor agonists used for weight loss and for treating type 2 #diabetes.
Read more in the news announcement: https://www.ema.europa.eu/en/news/ema-statement-ongoing-review-glp-1-receptor-agonists https://t.co/Rf3Ly9FGbM🐦🔗: https://n.respublicae.eu/EMA_News/status/1678794781256761346
-
EMA's #safety committee, the #PRAC, carried out its work to assess all aspects of risk management related to the use of #medicines.
More information in our meeting highlights: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-3-6-july-2023
#SafetyOfMedicines https://t.co/D0EHywwIMF🐦🔗: https://n.respublicae.eu/EMA_News/status/1677261762968662016
-
EMA's #safety committee, the #PRAC, carried out its work to assess all aspects of risk management related to the use of #medicines.
More information in our meeting highlights: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-3-6-july-2023
#SafetyOfMedicines https://t.co/D0EHywwIMF🐦🔗: https://n.respublicae.eu/EMA_News/status/1677261762968662016
-
At its June meeting, EMA's #safety committee, the #PRAC, carried out its work to assess all aspects of risk management related to the use of #medicines.
More information in our meeting highlights: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-5-8-june-2023
🐦🔗: https://n.respublicae.eu/EMA_News/status/1667127819984306176
-
At its June meeting, EMA's #safety committee, the #PRAC, carried out its work to assess all aspects of risk management related to the use of #medicines.
More information in our meeting highlights: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-5-8-june-2023
🐦🔗: https://n.respublicae.eu/EMA_News/status/1667127819984306176
-
At its June meeting, EMA's #safety committee, the #PRAC, carried out its work to assess all aspects of risk management related to the use of #medicines.
More information in our meeting highlights: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-5-8-june-2023
🐦🔗: https://n.respublicae.eu/EMA_News/status/1667127819984306176
-
At its June meeting, EMA's #safety committee, the #PRAC, carried out its work to assess all aspects of risk management related to the use of #medicines.
More information in our meeting highlights: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-5-8-june-2023
🐦🔗: https://n.respublicae.eu/EMA_News/status/1667127819984306176
-
If an unusual pattern emerged, the #PRAC performed an in-depth analysis of the reports to quickly identify potential safety issues with #Covid19vaccines.
The 🇪🇺 pharmacovigilance system showed that it can detect and manage emerging #safety issues quickly.
🐦🔗: https://n.respublicae.eu/EMA_News/status/1666080058241581057
-
If an unusual pattern emerged, the #PRAC performed an in-depth analysis of the reports to quickly identify potential safety issues with #Covid19vaccines.
The 🇪🇺 pharmacovigilance system showed that it can detect and manage emerging #safety issues quickly.
🐦🔗: https://n.respublicae.eu/EMA_News/status/1666080058241581057
-
If an unusual pattern emerged, the #PRAC performed an in-depth analysis of the reports to quickly identify potential safety issues with #Covid19vaccines.
The 🇪🇺 pharmacovigilance system showed that it can detect and manage emerging #safety issues quickly.
🐦🔗: https://n.respublicae.eu/EMA_News/status/1666080058241581057
-
We placed extra obligations on the #Covid19vaccine makers.
They had to provide us with detailed monthly reports on the #safety of their vaccine ➡️ 5⃣6⃣monthly reports were assessed by our safety committee, the #PRAC, until December 2022.
🐦🔗: https://n.respublicae.eu/EMA_News/status/1666079498784366597
-
We placed extra obligations on the #Covid19vaccine makers.
They had to provide us with detailed monthly reports on the #safety of their vaccine ➡️ 5⃣6⃣monthly reports were assessed by our safety committee, the #PRAC, until December 2022.
🐦🔗: https://n.respublicae.eu/EMA_News/status/1666079498784366597
-
We placed extra obligations on the #Covid19vaccine makers.
They had to provide us with detailed monthly reports on the #safety of their vaccine ➡️ 5⃣6⃣monthly reports were assessed by our safety committee, the #PRAC, until December 2022.
🐦🔗: https://n.respublicae.eu/EMA_News/status/1666079498784366597
-
EMA's #safety committee, the #PRAC, carried out its work to assess all aspects of risk management related to the use of #medicines.
More information in our meeting highlights: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-13-16-march-2023
🐦🔗: https://n.respublicae.eu/EMA_News/status/1636691621998673920
-
EMA's #safety committee, the #PRAC, carried out its work to assess all aspects of risk management related to the use of #medicines.
More information in our meeting highlights: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-13-16-march-2023
🐦🔗: https://n.respublicae.eu/EMA_News/status/1636691621998673920
-
EMA's #safety committee, the #PRAC, carried out its work to assess all aspects of risk management related to the use of #medicines.
More information in our meeting highlights: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-13-16-march-2023
🐦🔗: https://n.respublicae.eu/EMA_News/status/1636691621998673920
-
At its February meeting, EMA's safety committee, the #PRAC, started a safety review of medicines containing pseudoephedrine.
#PublicHealth #SafetyOfMedicines
🐦🔗: https://n.respublicae.eu/EMA_News/status/1624037832950939650
-
At its February meeting, EMA's safety committee, the #PRAC, started a safety review of medicines containing pseudoephedrine.
#PublicHealth #SafetyOfMedicines
🐦🔗: https://n.respublicae.eu/EMA_News/status/1624037832950939650
-
At its February meeting, EMA's safety committee, the #PRAC, started a safety review of medicines containing pseudoephedrine.
#PublicHealth #SafetyOfMedicines
🐦🔗: https://n.respublicae.eu/EMA_News/status/1624037832950939650
-
At its January meeting, our safety committee 🔎💊, the #PRAC, recommended aligning dose recommendations for Janus kinase inhibitors for chronic inflammatory disorders.
#chronicillness #SafetyOfMedicines
Read more in our highlights: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-9-12-january-2023
🐦🔗: https://n.respublicae.eu/EMA_News/status/1613886224040710148
-
At its January meeting, our safety committee 🔎💊, the #PRAC, recommended aligning dose recommendations for Janus kinase inhibitors for chronic inflammatory disorders.
#chronicillness #SafetyOfMedicines
Read more in our highlights: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-9-12-january-2023
🐦🔗: https://n.respublicae.eu/EMA_News/status/1613886224040710148
-
At its January meeting, our safety committee 🔎💊, the #PRAC, recommended aligning dose recommendations for Janus kinase inhibitors for chronic inflammatory disorders.
#chronicillness #SafetyOfMedicines
Read more in our highlights: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-9-12-january-2023
🐦🔗: https://n.respublicae.eu/EMA_News/status/1613886224040710148
-
RT @EMA_News: At its January meeting, our safety committee 🔎💊, the #PRAC, recommended aligning dose recommendations for Janus kinase inhibitors for chronic inflammatory disorders.
#chronicillness #SafetyOfMedicines
Read more in our highlights: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-9-12-january-2023
🐦🔗: https://n.respublicae.eu/Food_EU/status/1613888043802394627
-
RT @EMA_News: At its January meeting, our safety committee 🔎💊, the #PRAC, recommended aligning dose recommendations for Janus kinase inhibitors for chronic inflammatory disorders.
#chronicillness #SafetyOfMedicines
Read more in our highlights: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-9-12-january-2023
🐦🔗: https://n.respublicae.eu/Food_EU/status/1613888043802394627
-
RT @EMA_News: At its January meeting, our safety committee 🔎💊, the #PRAC, recommended aligning dose recommendations for Janus kinase inhibitors for chronic inflammatory disorders.
#chronicillness #SafetyOfMedicines
Read more in our highlights: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-9-12-january-2023
🐦🔗: https://n.respublicae.eu/Food_EU/status/1613888043802394627
-
EMA's safety committee, the #PRAC, finds no link between mRNA #COVID19vaccines and very rare cases of autoimmune hepatitis.
-
RT @EMA_News: EMA's safety committee, the #PRAC, finds no link between mRNA #COVID19vaccines and very rare cases of autoimmune hepatitis.
-
RT @EMA_News: EMA's safety committee, the #PRAC, finds no link between mRNA #COVID19vaccines and very rare cases of autoimmune hepatitis.
-
EMA's safety committee, the #PRAC, finds no link between mRNA #COVID19vaccines and very rare cases of autoimmune hepatitis.